Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

The researchers focused on the enzyme prohormone convertase 1/3, which plays a role in obesity and produces peptides like GLP-1, the target of semaglutide. Using an AI algorithm called Peptide ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

One of the peptide products is glucagon-like peptide 1, or GLP-1, which regulates appetite and blood sugar levels; semaglutide works by mimicking the effect of GLP-1 in the body. The team turned ...

Administration of semaglutide before metabolic and bariatric surgery does not confer benefits for overall weight loss, ...

The commercial success of the injectable peptide-based weight-loss drugs marketed by Novo Nordisk and Eli Lilly and Company ...

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor ... and reduce or slow down nutrient absorption. Popular natural fat burners include caffeine, green tea, and green ...

Let’s dive in. Semaglutide is in a class called glucagon-like peptide-1 (GLP-1) receptor agonists. It works by mimicking GLP-1, a hormone the intestines naturally make. GLP-1 plays a key role in ...

One of the peptide products is glucagon-like peptide 1, or GLP-1, which regulates appetite and blood sugar levels; semaglutide works by mimicking the effect of GLP-1 in the body. The team turned ...